logo
Plus   Neg
Share
Email

Stock Alert: Axsome Therapeutics Up 25% As Alzheimer's Drug Achieves Main Goal

Shares of Axsome Therapeutics, Inc. (AXSM) surged over 25% on Monday morning after the clinical-stage biopharmaceutical company's lead investigational drug for Alzheimer's disease agitation achieved positive results in a study.

AXSM is currently trading at $96.89, up $20.49 or 26.82%, on the Nasdaq.

Axsome Therapeutics announced that its investigational drug AXS-05 met the primary endpoint in the Phase 2/3 trial. The drug rapidly, substantially, and significantly improved agitation in patients with Alzheimer's disease as compared to placebo.

The study conducted on 366 Alzheimer's disease patients.

There are currently no FDA-approved treatments for Alzheimer's disease agitation. Alzheimer's disease is the most common form of dementia and is characterized by cognitive decline, and behavioral and psychological symptoms including agitation. Agitation is observed in up to 70% of patients with Alzheimer's disease.

AXS-05 has been granted FDA Fast Track designation for the treatment of Alzheimer's disease agitation.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration has approved the marketing of a new robotically-assisted surgical device (RASD) that can facilitate transvaginal hysterectomy in certain patients using minimally-invasive surgical instruments. The Hominis Surgical System of Memic Innovative Surgery Ltd., the U.S. subsidiary of Israeli biotechnology company memic Ltd., has been granted marketing authorization. Canadian cannabis company Canopy Growth Corp. (CGC, WEED.TO) announced Tuesday the launch of its Cannabidiol (CBD) beverage brand Quatreau in the high-potential U.S. market. Quatreau will be sold on Canopy's one-stop U.S. e-commerce destination, www.shopcanopy.com. Quatreau is a premium ready-to-drink... A Black Amazon.com Inc. manager filed a lawsuit against the e-commerce giant alleging gender and racial discrimination, sexual harassment, as well as violations of the Equal Pay Act. In the complaint filed in federal court in Washington, DC., Charlotte Newman, head of underrepresented founder startup business development at Amazon Web Services, accused the company of discriminating...
Follow RTT